Literature DB >> 12525621

Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents.

Darrell R Thomsen1, Nancee L Oien, Todd A Hopkins, Mary L Knechtel, Roger J Brideau, Michael W Wathen, Fred L Homa.   

Abstract

The 4-oxo-dihydroquinolines (PNU-182171 and PNU-183792) are nonnucleoside inhibitors of herpesvirus polymerases (R. J. Brideau et al., Antiviral Res. 54:19-28, 2002; N. L. Oien et al., Antimicrob. Agents Chemother. 46:724-730, 2002). In cell culture these compounds inhibit herpes simplex virus type 1 (HSV-1), HSV-2, human cytomegalovirus (HCMV), varicella-zoster virus (VZV), and human herpesvirus 8 (HHV-8) replication. HSV-1 and HSV-2 mutants resistant to these drugs were isolated and the resistance mutation was mapped to the DNA polymerase gene. Drug resistance correlated with a point mutation in conserved domain III that resulted in a V823A change in the HSV-1 or the equivalent amino acid in the HSV-2 DNA polymerase. Resistance of HCMV was also found to correlate with amino acid changes in conserved domain III (V823A+V824L). V823 is conserved in the DNA polymerases of six (HSV-1, HSV-2, HCMV, VZV, Epstein-Barr virus, and HHV-8) of the eight human herpesviruses; the HHV-6 and HHV-7 polymerases contain an alanine at this amino acid. In vitro polymerase assays demonstrated that HSV-1, HSV-2, HCMV, VZV, and HHV-8 polymerases were inhibited by PNU-183792, whereas the HHV-6 polymerase was not. Changing this amino acid from valine to alanine in the HSV-1, HCMV, and HHV-8 polymerases alters the polymerase activity so that it is less sensitive to drug inhibition. In contrast, changing the equivalent amino acid in the HHV-6 polymerase from alanine to valine alters polymerase activity so that PNU-183792 inhibits this enzyme. The HSV-1, HSV-2, and HCMV drug-resistant mutants were not altered in their susceptibilities to nucleoside analogs; in fact, some of the mutants were hypersensitive to several of the drugs. These results support a mechanism where PNU-183792 inhibits herpesviruses by interacting with a binding determinant on the viral DNA polymerase that is less important for the binding of nucleoside analogs and deoxynucleoside triphosphates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525621      PMCID: PMC140985          DOI: 10.1128/jvi.77.3.1868-1876.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Structure of the replicating complex of a pol alpha family DNA polymerase.

Authors:  M C Franklin; J Wang; T A Steitz
Journal:  Cell       Date:  2001-06-01       Impact factor: 41.582

2.  Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.

Authors:  S Chou; N S Lurain; A Weinberg; G Y Cai; P L Sharma; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase.

Authors:  V A Vaillancourt; M M Cudahy; S A Staley; R J Brideau; S J Conrad; M L Knechtel; N L Oien; J L Wieber; Y Yagi; M W Wathen
Journal:  Bioorg Med Chem Lett       Date:  2000-09-18       Impact factor: 2.823

4.  Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses.

Authors:  Roger J Brideau; Mary L Knechtel; Audris Huang; Valerie A Vaillancourt; Ellen E Vera; Nancee L Oien; Todd A Hopkins; Janet L Wieber; Karen F Wilkinson; Bob D Rush; Francis J Schwende; Michael W Wathen
Journal:  Antiviral Res       Date:  2002-04       Impact factor: 5.970

Review 5.  Non-nucleoside inhibitors of herpesviruses.

Authors:  Michael W Wathen
Journal:  Rev Med Virol       Date:  2002 May-Jun       Impact factor: 6.989

6.  A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.

Authors:  I Buerger; J Reefschlaeger; W Bender; P Eckenberg; A Popp; O Weber; S Graeper; H D Klenk; H Ruebsamen-Waigmann; S Hallenberger
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.

Authors:  James J Crute; Christine A Grygon; Karl D Hargrave; Bruno Simoneau; Anne-Marie Faucher; Gordon Bolger; Philip Kibler; Michel Liuzzi; Michael G Cordingley
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

8.  New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.

Authors:  Gerald Kleymann; Rüdiger Fischer; Ulrich A K Betz; Martin Hendrix; Wolfgang Bender; Udo Schneider; Gabriele Handke; Peter Eckenberg; Guy Hewlett; Veniamin Pevzner; Judith Baumeister; Olaf Weber; Kerstin Henninger; Jörg Keldenich; Axel Jensen; Jörg Kolb; Ute Bach; Andreas Popp; Jutta Mäben; Isabelle Frappa; Dieter Haebich; Oswald Lockhoff; Helga Rübsamen-Waigmann
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

9.  Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors.

Authors:  Nancee L Oien; Roger J Brideau; Todd A Hopkins; Janet L Wieber; Mary L Knechtel; John A Shelly; Robert A Anstadt; Peter A Wells; Roger A Poorman; Audris Huang; Vallerie A Vaillancourt; Terrance L Clayton; John A Tucker; Michael W Wathen
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

10.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more
  10 in total

1.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors:  Ning Li; Scott Thompson; Hualiang Jiang; Paul M Lieberman; Cheng Luo
Journal:  Expert Opin Drug Discov       Date:  2010-12       Impact factor: 6.098

Review 3.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Herpes virus genome, the pressure is on.

Authors:  David W Bauer; Jamie B Huffman; Fred L Homa; Alex Evilevitch
Journal:  J Am Chem Soc       Date:  2013-07-23       Impact factor: 15.419

Review 5.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Structural understanding of non-nucleoside inhibition in an elongating herpesvirus polymerase.

Authors:  Robert P Hayes; Mee Ra Heo; Mark Mason; John Reid; Christine Burlein; Kira A Armacost; David M Tellers; Izzat Raheem; Anthony W Shaw; Edward Murray; Philip M McKenna; Pravien Abeywickrema; Sujata Sharma; Stephen M Soisson; Daniel Klein
Journal:  Nat Commun       Date:  2021-05-24       Impact factor: 14.919

Review 7.  Recent highlights in the development of new antiviral drugs.

Authors:  Erik De Clercq
Journal:  Curr Opin Microbiol       Date:  2005-10       Impact factor: 7.934

Review 8.  Antivirals and antiviral strategies.

Authors:  Erik De Clercq
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

9.  Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures.

Authors:  C-Y Hsiang; T-Y Ho
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

Review 10.  Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase.

Authors:  D Topalis; S Gillemot; R Snoeck; G Andrei
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.